Verona Pharma plc (I9SA F) stock market data APIs
€89.1302
0(0%)
as of September 18, 2025
Try our APIs with
free plan!
Verona Pharma plc Financial Data Overview
Price chart is built with
Anychart
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Prev. Close
89.1302
Open
89.1349
High
89.1302
Low
88.1515
52 wk Range
24.2-92.2
Market Cap
11 999 M
Shares Outstanding
86 496 K
Revenue
222 M
EPS
-0.23
Beta
0.135
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Verona Pharma plc data using free add-ons & libraries
Get Verona Pharma plc Fundamental Data
Verona Pharma plc Fundamental data includes:
- Net Revenue: 222 M
- EBITDA: -52 737 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2022-11-09
- EPS/Forecast: -0.16
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Verona Pharma plc News
New
Verona Pharma (VRNA) Rebounded from Challenging Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The small...
Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025
Verona Pharma plc Posters support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE...
Does Verona Pharma's Recent FDA Approval Rally Signal Further Upside in 2025?
If you have been watching Verona Pharma, you are likely wondering whether now is the right time to get in, hold steady, or take some profit off the table. With shares closing recently at $106.43 and a...
Here’s What Boosted Verona Pharma plc (VRNA) Share Price by 49%
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded h...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
